ATE321134T1 - Menschlicher fc-gamma-rezeptor iii - Google Patents

Menschlicher fc-gamma-rezeptor iii

Info

Publication number
ATE321134T1
ATE321134T1 AT97106398T AT97106398T ATE321134T1 AT E321134 T1 ATE321134 T1 AT E321134T1 AT 97106398 T AT97106398 T AT 97106398T AT 97106398 T AT97106398 T AT 97106398T AT E321134 T1 ATE321134 T1 AT E321134T1
Authority
AT
Austria
Prior art keywords
human
gamma receptor
receptor iii
variants
image
Prior art date
Application number
AT97106398T
Other languages
English (en)
Inventor
Gary A Peltz
Kevin W Moore
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE321134T1 publication Critical patent/ATE321134T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
AT97106398T 1988-05-27 1989-05-24 Menschlicher fc-gamma-rezeptor iii ATE321134T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19951388A 1988-05-27 1988-05-27
US30003989A 1989-01-19 1989-01-19

Publications (1)

Publication Number Publication Date
ATE321134T1 true ATE321134T1 (de) 2006-04-15

Family

ID=26894851

Family Applications (2)

Application Number Title Priority Date Filing Date
AT89305241T ATE197053T1 (de) 1988-05-27 1989-05-24 Humaner rezeptor fc(gamma)riii
AT97106398T ATE321134T1 (de) 1988-05-27 1989-05-24 Menschlicher fc-gamma-rezeptor iii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT89305241T ATE197053T1 (de) 1988-05-27 1989-05-24 Humaner rezeptor fc(gamma)riii

Country Status (10)

Country Link
US (2) US5976831A (de)
EP (3) EP0791653B9 (de)
JP (1) JP2657221B2 (de)
KR (1) KR0149012B1 (de)
AT (2) ATE197053T1 (de)
AU (1) AU3740089A (de)
DE (3) DE68929546D1 (de)
ES (2) ES2262163T3 (de)
GR (1) GR3034698T3 (de)
WO (1) WO1989011490A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767077A (en) * 1988-05-27 1998-06-16 Applied Research Systems Ars Holding N.V. Human Fc-γ receptor III
EP0791653B9 (de) 1988-05-27 2006-08-30 Applied Research Systems ARS Holding N.V. Menschlicher Fc-gamma-Rezeptor III
US7038031B1 (en) * 1989-07-28 2006-05-02 Sloan-Kettering Institute For Cancer Research DNA encoding FcγR receptor protein on NK cells
FR2655269B1 (fr) * 1989-12-01 1994-02-11 Curie Universite Pierre Marie Proteines empechant l'interaction entre un fragment fc d'une immunoglobuline et son recepteur et utilisation en therapeutique, notamment dans le traitement des affections liees aux virus hiv.
FR2702481B1 (fr) * 1993-03-09 1995-04-28 Roussel Uclaf Nouveaux récepteurs Fc-gamma III humains solubles, leur procédé de préparation, les compositions pharmaceutiques les contenant, leur application comme médicaments et leur application diagnostique.
US5641875A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania DNA encoding chimeric IgG Fc receptor
AU8116494A (en) * 1993-11-12 1995-06-13 Kenichi Matsubara Gene signature
US6444789B1 (en) 1995-05-03 2002-09-03 Applied Research Systems Ars Holding N.V. CD16-II variants
FR2739560B1 (fr) * 1995-10-09 1997-11-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite du cd16 humain soluble dans le traitement de l'infection par le virus vih
US7287836B2 (en) * 1997-07-15 2007-10-30 Sil;Verbrook Research Pty Ltd Ink jet printhead with circular cross section chamber
US7465030B2 (en) 1997-07-15 2008-12-16 Silverbrook Research Pty Ltd Nozzle arrangement with a magnetic field generator
US6935724B2 (en) 1997-07-15 2005-08-30 Silverbrook Research Pty Ltd Ink jet nozzle having actuator with anchor positioned between nozzle chamber and actuator connection point
US6648453B2 (en) 1997-07-15 2003-11-18 Silverbrook Research Pty Ltd Ink jet printhead chip with predetermined micro-electromechanical systems height
US6855264B1 (en) 1997-07-15 2005-02-15 Kia Silverbrook Method of manufacture of an ink jet printer having a thermal actuator comprising an external coil spring
US7468139B2 (en) 1997-07-15 2008-12-23 Silverbrook Research Pty Ltd Method of depositing heater material over a photoresist scaffold
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US7195339B2 (en) 1997-07-15 2007-03-27 Silverbrook Research Pty Ltd Ink jet nozzle assembly with a thermal bend actuator
US7556356B1 (en) 1997-07-15 2009-07-07 Silverbrook Research Pty Ltd Inkjet printhead integrated circuit with ink spread prevention
US6712453B2 (en) 1997-07-15 2004-03-30 Silverbrook Research Pty Ltd. Ink jet nozzle rim
EP1006183A1 (de) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinante, lösliche Fc-Rezeptoren
DK1436427T3 (da) * 2001-10-19 2008-12-08 Chru Tours Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons
EP1513554B9 (de) * 2002-05-30 2011-11-09 Macrogenics, Inc. Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (de) 2003-01-09 2011-09-28 Macrogenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
EP2052713A3 (de) * 2003-01-13 2009-05-20 Macrogenics, Inc. Lösliche FcgammaR-Fusionsproteine und Verfahren zu deren Verwendung
MXPA06012601A (es) 2004-05-10 2007-05-10 Macrogenics Inc Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
US20070231813A1 (en) * 2004-06-01 2007-10-04 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies
US20070190657A1 (en) * 2004-06-15 2007-08-16 Universite Francois Rabelais Methods of assessing susceptibility to drug-induced thrombocytopenia
EP2801583B1 (de) 2004-07-10 2018-04-25 Fox Chase Cancer Center Gentechnisch veränderte menschliche natürliche Killerzelllinien
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
AU2006272204A1 (en) 2005-07-21 2007-01-25 Genmab A/S Potency assays for antibody drug substance binding to an Fc receptor
CA2618681C (en) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
EP2032159B1 (de) 2006-06-26 2015-01-07 MacroGenics, Inc. Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
PT2029173T (pt) 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
PL2247304T3 (pl) 2008-04-02 2017-01-31 Macrogenics, Inc. Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
CN102666874B (zh) 2009-10-07 2016-06-01 宏观基因有限公司 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
MY156743A (en) 2009-12-21 2016-03-31 Regeneron Pharma Humanized fc?r mice
US8883496B2 (en) 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
EP2492689B8 (de) * 2011-02-22 2013-12-25 Bernhard-Nocht-Institut für Tropenmedizin Nachweis von Antikörpern mit einem verbesserten Immunkomplex- (IC) ELISA
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
ES2794942T3 (es) 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
CN106574261B (zh) * 2014-06-27 2021-02-05 东曹株式会社 改良Fc结合蛋白、及制造方法、使用该蛋白的抗体吸附剂和使用该吸附剂的抗体分离方法
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199153A (en) * 1878-01-15 Improvement in sulky-plows
NZ220504A (en) * 1986-05-29 1991-09-25 Univ Melbourne Fc receptor site an immunoglobulin and dna sequences encodng it
FR2611913B1 (fr) * 1987-02-24 1994-04-15 Khayat David Procede de dosage des recepteurs fc gamma solubles seriques, coffret de dosage correspondant et applications
WO1989008114A1 (en) * 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
EP0791653B9 (de) * 1988-05-27 2006-08-30 Applied Research Systems ARS Holding N.V. Menschlicher Fc-gamma-Rezeptor III

Also Published As

Publication number Publication date
DE68929546D1 (de) 2006-05-11
AU3740089A (en) 1989-12-12
ES2262163T3 (es) 2006-11-16
WO1989011490A1 (en) 1989-11-30
ES2150898T3 (es) 2000-12-16
EP0343950B1 (de) 2000-10-18
EP0449828A1 (de) 1991-10-09
EP0791653B9 (de) 2006-08-30
KR0149012B1 (ko) 1998-08-17
DE68929256D1 (de) 2000-11-23
EP0343950A2 (de) 1989-11-29
HK1001403A1 (en) 1998-06-19
DE68929256T2 (de) 2001-05-17
EP0791653A1 (de) 1997-08-27
GR3034698T3 (en) 2001-01-31
ATE197053T1 (de) 2000-11-15
KR900701843A (ko) 1990-12-04
DE68929546T4 (de) 2007-03-08
JPH03501484A (ja) 1991-04-04
US5976831A (en) 1999-11-02
JP2657221B2 (ja) 1997-09-24
EP0791653B1 (de) 2006-03-22
EP0343950A3 (de) 1991-07-10
DE68929546T2 (de) 2006-09-21
US6294347B1 (en) 2001-09-25

Similar Documents

Publication Publication Date Title
ATE321134T1 (de) Menschlicher fc-gamma-rezeptor iii
DK1266965T3 (da) Rekombinante antistoffer til human terapi
DE3789973D1 (de) Zahnimplantat zur Befestigung von Zahnersatz-Suprakonstruktionen.
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
EP0261224A4 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
ATE162079T1 (de) Verwendung von antikörper enthaltenden präparationen zur immunsuppression
DK228190A (da) Rajgraespollenallergen
DK175843B1 (da) Polypeptider af overfladeaktive alvelolarproteiner (ASP), farmaceutisk sammensætning indeholdende polypeptidet, DNA-ekspressionssystem der koder for polypeptidet, samt fremgangsmåde til fremstilling af polypeptider med ASP-aktivitet
NO882388D0 (no) Fremgangsmaate til opparbeidelse av kontaminerte mineralstoffer.
DE68921908D1 (de) Zell-assoziierte Glucosyltransferase, Antikörper dagegen und eine diese enthaltende Zusammensetzung zur Prophylaxe von Karies.
DE3852625D1 (de) Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C.
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
NO893794L (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
PT524421E (pt) Herpesvirus humano tipo 6 proteina p 100, sequencias de adn correspondentes, preparacao e utilizacao
DK319384D0 (da) 1-0-alkyl-3-amino-propan-1,2-diol-2-0-phospholipider, fremgangsmaade til deres fremstilling samt farmaceutiske praeparater indeholdende disse
IL86710A0 (en) Polypeptide receptor for interleukin-2,antibodies against this polypeptide and pharmaceutical compositions containing the same
NO170936C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive, substituerte vinylcefalosporiner
DE3872790D1 (de) Geraet zur untersuchung von reissverschlusselementen.
BR6802052U (pt) Mascara cirurgica descartavel retangular com cadarcos costurados pelo sistema hrow(hight resfst one way)
NO893795D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO875477D0 (no) Rekombinant alveolaert overflateaktivt protein.
EP0511516A3 (en) Schizosaccharomyces specific polypeptide
NO881501D0 (no) Rekombinante htlv-111 proteiner og anvendelse av disse.
IT8320809V0 (it) Chiusura per flaconi e simili particolarmente per uso farmaceutico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0791653

Country of ref document: EP

EELA Cancelled due to lapse of time